These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37985066)

  • 1. β-Glucan-conjugated anti-PD-L1 antibody enhances antitumor efficacy in preclinical mouse models.
    Wang Q; Jiang H; Zhang H; Lu W; Wang X; Xu W; Li J; Lv Y; Li G; Cai C; Yu G
    Carbohydr Polym; 2024 Jan; 324():121564. PubMed ID: 37985066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model.
    Hu X; Shui Y; Hirano H; Kusano K; Guo WZ; Fujino M; Li XK
    Cancer Immunol Immunother; 2023 Mar; 72(3):719-731. PubMed ID: 36053290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
    Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
    Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy.
    He L; Wang L; Wang Z; Li T; Chen H; Zhang Y; Hu Z; Dimitrov DS; Du J; Liao X
    J Med Chem; 2021 Nov; 64(21):15716-15726. PubMed ID: 34730979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
    Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
    Wen X; Shi C; Zeng X; Zhao L; Yao L; Liu Z; Feng L; Zhang D; Huang J; Li Y; Lin Q; Chen H; Zhuang R; Chen X; Zhang X; Guo Z
    Clin Cancer Res; 2022 Jul; 28(13):2923-2937. PubMed ID: 35320358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer.
    Wang M; Bai Y; Pei J; Li D; Pu X; Zhu W; Xia L; Qi C; Jiang H; Ning Y
    Front Pharmacol; 2022; 13():887457. PubMed ID: 35548349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
    Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
    Ko HH; Peng HH; Cheng AN; Chou HE; Hou HH; Kuo WT; Liu WW; Kuo MY; Lee AY; Cheng SJ
    Cancer Sci; 2023 Oct; 114(10):3857-3872. PubMed ID: 37525561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
    Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
    J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspergillus fumigatus Cell Wall α-(1,3)-Glucan Stimulates Regulatory T-Cell Polarization by Inducing PD-L1 Expression on Human Dendritic Cells.
    Stephen-Victor E; Karnam A; Fontaine T; Beauvais A; Das M; Hegde P; Prakhar P; Holla S; Balaji KN; Kaveri SV; Latgé JP; Aimanianda V; Bayry J
    J Infect Dis; 2017 Dec; 216(10):1281-1294. PubMed ID: 28968869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.